S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology|
|ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia|
|ARIAD Reports Third Quarter 2014 Financial Results and Development Progress|
|ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial|
|ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency|
|ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia|
|ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial|
|ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe|
|ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer|
|ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib|
Click above to view more mutual fund data and stats for aria - ARIAD Pharmaceuticals Inc.